Treatment Patterns, Biochemical Profiles and Clinical Outcomes in Adults With X-Linked Hypophosph… (NCT07607600) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Treatment Patterns, Biochemical Profiles and Clinical Outcomes in Adults With X-Linked Hypophosphatemia
United States, Australia, Canada100 participantsStarted 2026-07-07
Plain-language summary
The purpose of this study is to better understand how X-linked hypophosphatemia (XLH) affects the body and daily life. Phosphate levels are critical in managing XLH, we aim to study how these levels change in patients taking burosumab and how they relate to bone health, overall disease burden and XLH-related conditions.
Who can participate
Age range
18 Years – 64 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Informed consent obtained before any trial-related activities, i.e., any procedure related to recording of data according to the protocol.
* Male or female and aged 18-64 years (both inclusive) at the time of signing informed consent.
* Diagnosis of congenital XLH, confirmed genetically or clinically as determined by the investigator, supported by documentation.
* Participants have been treated with burosumab for at least 90 days prior to the screening/baseline visit and treatment is still ongoing.
* Participant confirms ability and willingness to attend visits according to routine clinical care and mandatory assessments at the site.
Exclusion Criteria:
* Previous rescreening for this trial.
* Current participation in any interventional clinical trial. Participation in another non-interventional trial, such as a patient registry trial, is permitted.
* Any condition not associated with XLH, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Average Trough Serum Phosphate Concentration
Timeframe: From baseline to last assessment (Up to 3 years)